FDA has approved Otulfi (ustekinumab-aauz), a ustekinumab biosimilar for the treatment of Crohn’s disease, ulcerative colitis, moderate to severe plaque psoriasis and active psoriatic arthritis. Otulfi ismade by Fresenius Kabi and Formycon https://t.co/p2h9X0C16W https://t.co/YD0uJSEbaq
Links:
Fresenius Kabi and Formycon Receive U.S. FDA Approval for Biosimilar Otulfi™* (…
https://buff.ly/3XROqdd
Oct-05-2024
